Request your welcome kit today
We recognize every patient journey is unique, and we are here to provide resources that empower both you and your patients to make more informed decisions on their therapeutic selection. Resources include:
- NCCN breast cancer guidelines
- Key insights from the TAILORx and RxPONDER studies
- Patient education brochures for your office
- Annotated sample reports
- Introduction to our precision oncology portfolio
- Helpful guide to the Exact Sciences Provider Ordering Hub
Footnotes
Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.
The Oncotype DX Breast Recurrence Score test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority.